Checking a Blood Test Method for Low-Dose Rituximab in Rheumatoid Arthritis
Studies whether a drug-level model predicts response to one rituximab dose in adults with arthritis.
Plain-language title generated from the registry record
Registry title: Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis
Key facts
- Where
- Tours, FranceSee the site
Where in France
- University hospitalTours, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Tours
- Trial code
- NCT06933134
- Record updated
- 30 April 2026
- Original description
Evaluation of the prediction of clinical response to rituximab at a dose of 1000 mg once using a pharmacological model including several pharmacokinetic and pharmacodynamic parameters.Read full original descriptionShow less
Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis
Evaluation of the prediction of clinical response to rituximab at a dose of 1000 mg once using a pharmacological model including several pharmacokinetic and pharmacodynamic parameters.
Inclusion: . Age ≥ 18 years; Diagnosis of rheumatoid arthritis meeting ACR/EULAR 2010 criteria; Candidates for a Low Dose regimen: on standard dose rituximab and with a good clinical response according to the referring rheumatologist. No maximum duration of use of standard-dose rituximab has been defined; In the case of co-prescription of csDMARDs (Methotrexate, Leflunomide, Salazopyrine, Plaquenil), the dose must have been stable for 3 months; If corticosteroids are co-prescribed, the dose should be ≤ 10 mg/d and stable for 3 months.
Exclusion: Other associated targeted disease-modifying therapy; Sjögren's syndrome or other associated inflammatory rheumatism; Fibromyalgia or other pathology having an impact on the assessment of disease activity; Any active haematological disease affecting lymphocytes (chronic lymphocytic leukaemia, Hodgkin's and non-Hodgkin's lymphomas, lymphoplasmacytic lymphoma, T lymphoma); Opposition to data processing; No inclusion of persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code (e.g. minors, protected adults, etc.).